302 related articles for article (PubMed ID: 16257308)
1. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.
Stroman DW; Dajcs JJ; Cupp GA; Schlech BA
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S16-31. PubMed ID: 16257308
[TBL] [Abstract][Full Text] [Related]
2. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
Schlech BA; Alfonso E
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S7-15. PubMed ID: 16257313
[TBL] [Abstract][Full Text] [Related]
3. Safety of moxifloxacin as shown in animal and in vitro studies.
McGee DH; Holt WF; Kastner PR; Rice RL
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S46-54. PubMed ID: 16257310
[TBL] [Abstract][Full Text] [Related]
4. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans.
Robertson SM; Curtis MA; Schlech BA; Rusinko A; Owen GR; Dembinska O; Liao J; Dahlin DC
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S32-45. PubMed ID: 16257309
[TBL] [Abstract][Full Text] [Related]
5. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Scoper SV
Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Caballero AR; Marquart ME; O'Callaghan RJ; Thibodeaux BA; Johnston KH; Dajcs JJ
Curr Eye Res; 2006 Jan; 31(1):23-9. PubMed ID: 16421016
[TBL] [Abstract][Full Text] [Related]
7. Ophthalmic infections and their anti-infective challenges.
Alfonso E; Crider J
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S1-6. PubMed ID: 16257307
[TBL] [Abstract][Full Text] [Related]
8. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
[TBL] [Abstract][Full Text] [Related]
9. Future of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
Schlech BA; Blondeau J
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S64-7. PubMed ID: 16257312
[TBL] [Abstract][Full Text] [Related]
10. Fourth-generation fluoroquinolone-resistant bacterial keratitis.
Jhanji V; Sharma N; Satpathy G; Titiyal J
J Cataract Refract Surg; 2007 Aug; 33(8):1488-9. PubMed ID: 17662450
[TBL] [Abstract][Full Text] [Related]
11. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans.
McCulley JP; Caudle D; Aronowicz JD; Shine WE
Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244
[TBL] [Abstract][Full Text] [Related]
12. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Sanders ME; Moore QC; Norcross EW; Sanfilippo CM; Hesje CK; Shafiee A; Marquart ME
Cornea; 2011 Jan; 30(1):83-90. PubMed ID: 20847656
[TBL] [Abstract][Full Text] [Related]
13. Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.
Moshirfar M; Mirzaian G; Feiz V; Kang PC
J Cataract Refract Surg; 2006 Mar; 32(3):515-8. PubMed ID: 16631067
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.
Hwang DG
Surv Ophthalmol; 2004 Mar; 49 Suppl 2():S79-83. PubMed ID: 15028483
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin.
O'Brien TP; Arshinoff SA; Mah FS
J Cataract Refract Surg; 2007 Oct; 33(10):1790-800. PubMed ID: 17889778
[TBL] [Abstract][Full Text] [Related]
16. Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers.
Shah VM; Tandon R; Satpathy G; Nayak N; Chawla B; Agarwal T; Sharma N; Titiyal JS; Vajpayee RB
Cornea; 2010 Jul; 29(7):751-7. PubMed ID: 20489580
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Sanders ME; Norcross EW; Moore QC; Shafiee A; Marquart ME
Cornea; 2009 Oct; 28(9):1055-60. PubMed ID: 19724203
[TBL] [Abstract][Full Text] [Related]
18. Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusis.
Moshirfar M; Meyer JJ; Espandar L
J Cataract Refract Surg; 2007 Nov; 33(11):1978-81. PubMed ID: 17964409
[TBL] [Abstract][Full Text] [Related]
19. One-day application of topical moxifloxacin 0.5% to select for fluoroquinolone-resistant coagulase-negative Staphylococcus.
He L; Ta CN; MiƱo de Kaspar H
J Cataract Refract Surg; 2009 Oct; 35(10):1715-8. PubMed ID: 19781465
[TBL] [Abstract][Full Text] [Related]
20. Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
Balzli CL; McCormick CC; Caballero AR; Huang B; Wigington L; Smith E; Tang A; O'Callaghan RJ
J Cataract Refract Surg; 2008 Feb; 34(2):295-301. PubMed ID: 18242457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]